Entrevestor: Densitas Partners with U.S. Beta User

Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.

See full article here

News Release: Precision BioLogic Launches Product to Improve Inhibitor Testing for People with Hemophilia A

HALIFAX, February 11, 2019—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities last month.
The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A. Because of this, it is important for clinical laboratories to have a testing system that can accurately and precisely quantify FVIII inhibitors in patient samples.
Follow link above to read full release

See full news release here